Home Cart Sign in  
Chemical Structure| 850879-09-3 Chemical Structure| 850879-09-3
Chemical Structure| 850879-09-3

*Storage: Sealed in dry,Room Temperature.

Amuvatinib

CAS No.: 850879-09-3

Amuvatinib is a multi-target inhibitor that inhibits c-Kit, PDGFRα, and Flt3 with IC50 values of 10 nM, 40 nM, and 81 nM, respectively. It also inhibits c-MET, c-RET, and Rad51, a DNA repair protein.

Synonyms: MP470;HPK 56

4.5 *For Research Use Only !

Cat. No.: A205668 Purity: 99%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
1mg łË§¶ÊÊ In Stock In Stock Login
5mg łÍó¶ÊÊ In Stock In Stock Login
10mg łď§¶ÊÊ In Stock In Stock Login
25mg łÇ˧¶ÊÊ Inquiry In Stock Login
50mg łÇîó¶ÊÊ In Stock In Stock Login
100mg ł§Çî¶ÊÊ Inquiry In Stock Login
250mg łÿò§¶ÊÊ Inquiry Inquiry Login

Please Login or Create an Account to: See VIP prices and availability

  • 1mg

    łË§¶ÊÊ

  • 5mg

    łÍó¶ÊÊ

  • 10mg

    łď§¶ÊÊ

  • 25mg

    łÇ˧¶ÊÊ

  • 50mg

    łÇîó¶ÊÊ

  • 100mg

    ł§Çî¶ÊÊ

  • 250mg

    łÿò§¶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Details of [ Amuvatinib ]

CAS No. :850879-09-3
Formula : C23H21N5O3S
M.W : 447.51
SMILES Code : S=C(N1CCN(C2=C(OC3=CC=CC=C34)C4=NC=N2)CC1)NCC5=CC=C(OCO6)C6=C5
Synonyms :
MP470;HPK 56
MDL No. :MFCD16038298
InChI Key :FOFDIMHVKGYHRU-UHFFFAOYSA-N
Pubchem ID :11282283

Safety of [ Amuvatinib ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Biological Activity

Target
  • PDGFRα

    PDGFRα (V561D), IC50:40 nM

  • c-Kit

    c-Kit (D816H), IC50:10 nM

  • FLT3

    FLT3 (D835Y), IC50:81 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01357395 Small Cell Lung Carcinoma PHASE2 COMPLETED 2012-05-28 University of Colorado Cancer ... More >>Center, Aurora, Colorado, 80045, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, United States|Washington University School of Medicine, Saint Louis, Missouri, 63108, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, 37404, United States|Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Wojewódzki Szpital Specjalistyczny, Radom, Mazowieckie, 26-617, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie, Warszawa, Mazowieckie, 02-781, Poland|Wojewódzki Szpital im. ?w. Ojca Pio w Przemy?lu Oddzia? Onkologiczny z Pododdzia?em Dziennej Chemioterapii, Przemy?l, Podkarpackie, 37-700, Poland|Wojewódzkie Centrum Onkologii, Gdansk, Pomorskie, 80-219, Poland|Specjalistyczny Szpital im. Alfreda Sokolowskiego, Szczecin, Zachodniopomorskie, 70-891, Poland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.17mL

2.23mL

1.12mL

22.35mL

4.47mL

2.23mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories